Information about Ticagrelor
Ticagrelor is an oral antiplatelet drug that is used with low dose aspirin to decrease the risk of myocardial infarction and stroke in patients with acute coronary syndromes.
Liver safety of Ticagrelor
Ticagrelor has been linked to rare instances of hypersensitivity reactions accompanied by mild liver injury.
Mechanism of action of Ticagrelor
Ticagrelor (tye ka' grel or) is a non-thienopyridine, reversible inhibitor of adenosine diphosphate (ADP) receptors (P2Y 12) on platelets and is used to decrease the risk of recurrent coronary thromboses in patients who undergo interventions during an acute coronary syndrome. Activated platelets release ADP which binds to ADP platelet receptors, causing activation of intracellular glycoprotein IIb/IIIA complex which triggers platelet adherence and aggregation. The aggregation of platelets plays an important role in the growth of atheromatous plaques, which can lead to coronary, cerebral and peripheral arterial occlusions. In clinical trials, ticagrelor therapy during acute coronary events (unstable angina and myocardial infarction) has been shown to decrease the frequency of recurrence of myocardial infarction and stent thrombosis.
FDA approval information for Ticagrelor
Ticagrelor was approved for use in the United States in 2011 and has been used in limited numbers of patients for a limited time only. Current indications are reduction of recurrent cardiovascular events in patients with acute coronary syndromes.
Dosage and administration for Ticagrelor
Ticagrelor is available in 90 mg tablets under the commercial name Brilinta. The usual maintenance dose is 90 mg twice daily in combination with daily low dose aspirin (<100 mg).
Side effects of Ticagrelor
Side effects are not common, but can include bleeding (12%), dyspnea (14%), headaches, nausea, diarrhea, hypotension and hypersensitivity reactions.